Industry Insights

  1. What It's Like To Advance A Cell Therapy Through The Japan Entry Acceleration Program 6/15/2026

    Ernexa Therapeutics President & CEO Sanjeev Luther details having one the of 10 coveted spots in the Japan Entry Acceleration Program (JEAP) that supports cell therapy development and market entry in Japan.

  2. A Blueprint For Addressing Underserved Patient Populations 6/12/2026

    Does our current approach to clinical research truly serve the patients who face the greatest needs? Insmed Inc. CMO Martina Flammer, MD, MBA, explores how to better meet patient needs.

  3. TrialScope EXTRA Keynotes Address Data Ownership, Health Communication 6/11/2026

    Can your regulatory and protocol strategies keep pace with evolving data ownership, disclosure, and AI requirements? Explore key compliance risks, protections, and practical solutions.

  4. Why Clinical Data Standards Matter In An AI-Driven World 6/11/2026

    Novartis technology and scientific computing expert Bill Illis discusses what changes sponsors must make to the R&D data landscape to achieve sustained, meaningful progress — with the help of AI — to bring new therapies to patients faster.

  5. How The Quiet Data Standards Revolution Is Impacting Drug Approval 6/11/2026

    Principal Statistical Programmer Varun Debbeti details the role data standards play in approval timelines, detailing shortfalls of current the model and CORE, Dataset-JSON, and SDTM v3.0 stand to make an impact.

  6. How Pharmacometrics Informs Dose Selection And Biomarker Decisions 6/10/2026

    Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

  7. Designing Trials For Disease Modification: Cereno Scientific's Approach To Pulmonary Arterial Hypertension 6/10/2026

    Cereno Scientific’s Rahul Agrawal discusses the scientific and strategic rationale behind extending the company’s Phase 2b study duration and how the company incorporated regulator and patient input.

  8. Why Early Clinical Development Is Shifting Toward Decision-Enabling Study Designs 6/9/2026

    Early clinical research is shifting to decision-focused designs, using biomarkers, functional endpoints, and targeted populations to reduce uncertainty and enable clearer progression.

  9. What Clinical Trial Management Solutions Don't Cover: The Ocular Endpoint Execution Gap 6/9/2026

    Discover how specialized endpoint execution closes critical gaps in ophthalmic trials, improving assessment consistency, protocol adherence, data quality, and participant retention.

  10. Clinical Research Logistics: How Point-Of-Need Execution Protects Ocular Endpoints 6/9/2026

    Reduce operational risk in ophthalmic trials with point-of-need execution. Discover how mobile clinics, specialized teams, and single-call accountability protect endpoint quality and study timelines.